News on Medial

Proptech startup Flent raises Rs 6.5 Cr in pre-seed round

EntrackrEntrackr ยท 9m ago
Proptech startup Flent raises Rs 6.5 Cr in pre-seed round
Medial

Proptech startup Flent has raised Rs 6.5 crore in its pre-seed round led by WEH Ventures, with participation from US-based 2 AM Ventures, Pareto Holdings, and a group of angel investors, including Sanchan S Saxena (ex-GM, Airbnb), Aneesh Reddy (founder, Capillary Technologies), Arjun Vaidya (founder, Dr. Vaidyaโ€™s), and Abhilash N (co-founder, Ivy Homes). The proceeds will be used to expand its core team and further develop full stack renting platform, which aims to make renting 10X easier and faster for Indiaโ€™s new-age working professionals. Founded by Shail Daswani, Mayank Lalwani, and Rishabh Agnihotri, the startup claims to have seen good traction for its flagship product Flent Reserve. Within 15 days of signing up and sharing their preferences, customers can move into a fully furnished, designer turnkey home with zero brokerage, a minimal deposit, and flexible stays ranging from 3 to 11 months. Since its inception in October 2023, Flent has launched 120 rooms across Bengaluru, from 1 BHKs to 3 BHKs, all of which have been rented out within 10 days of launch. The company already has a waitlist of over 500 people and has consistently achieved 100% occupancy. For homeowners, Flent manages the entire process, from property acquisition to furnishing and turning homes into turnkey rentals.

Related News

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group

EntrackrEntrackr ยท 6d ago
Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group
Medial

Lamark Biotech raises Rs 6.5 Cr in pre-Series A round led by IAN Group Lamark's proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. Biopharma startup Lamark Biotech has raised Rs 6.5 crore in a pre-Series A round led by IAN Group, including IAN Alpha Fund, powered by BioAngels, Vinayender Tulla, Nita Roy, and Venkataraman KNK. Domain experts from IANโ€™s angel investors led the round. The Ahmedabad-based company had previously raised $41.3K in a seed funding round led by VIT-TBI and others. The fresh funds will be utilized to accelerate the development of thermostable insulin and expand the biologics platform for global access, Lamark said in a press release. Founded in 2018 by Vaibhav Bhatia, Lamark Biotech aims to reimagine drug delivery for chronic and life-altering diseases. Its proprietary ProteoStrong platform enables the stabilization of fragile protein-based drugs, such as insulin, monoclonal antibodies, and enzymes, without altering their molecular structure. According to Lamark Biotech, it leverages the R&D base of Venture Center, NCL Innovation, and it is advancing a new class of temperature-resilient biologics that retain potency across extreme conditionsโ€”ideal for underserved regions where cold storage infrastructure is limited. With its lead program, InsulinStrong, Lamark is targeting the Rs 4,000 crore Indian insulin market and intends to expand across Southeast Asia and the UAE. In the next 24 months, it plans to file new international patents, begin early clinical trials, and build partnerships with pharma companies, CDMOs, and global health agencies.

Download the medial app to read full posts, comements and news.